Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2023 12:00 ET | Source: Beta Bionics, Inc.

Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System

CONCORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a clinical-stage medical technology company — announced the appointment of Steven Russell, MD, Ph.D., to the role of Chief...
August 15, 2022 16:00 ET | Source: Beta Bionics, Inc.

Beta Bionics Appoints Sean Saint as CEO and Board Member

Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational devices limited by Federal (or United States) law to investigational use. Not available for sale. CONCORD, Mass., Aug. 15, 2022 ...
June 09, 2022 14:00 ET | Source: Beta Bionics, Inc.

The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA’s 82nd Scientific Sessions

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The randomized Insulin-Only Bionic Pancreas...
June 01, 2022 05:00 ET | Source: Beta Bionics, Inc.

Pivotal Trial Results of the iLet® Bionic Pancreas to Be Presented at the ADA’s 82nd Scientific Sessions

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Roy W. Beck will moderate a session: The...
May 10, 2022 05:00 ET | Source: Beta Bionics, Inc.

Beta Bionics Appoints Gilad Glick to the Board of Directors and Veena Rao, Ph.D. as Chief Commercial Officer

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Gilad Glick, former Chief Executive Officer,...
April 30, 2022 04:00 ET | Source: Beta Bionics, Inc.

The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes

The trial achieved key primary and secondary endpoints, demonstrating improved outcomes over standard of care for people living with type 1 diabetes.The study population — 440 adults and children 6...
April 25, 2022 05:00 ET | Source: Beta Bionics, Inc.

Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD

Dr. Steven J. Russell will present the results from the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial at the International Conference on Advanced Technologies & Treatments for...
March 02, 2022 16:15 ET | Source: Beta Bionics, Inc.

Beta Bionics Announces Executive Leadership and Board Transitions in Preparation for Commercialization of the iLet® Bionic Pancreas System

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Ed Damiano, President & CEO of Beta...
February 17, 2022 16:00 ET | Source: Beta Bionics, Inc.

Beta Bionics Announces Closing of $57 Million Series C Financing

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The financing round was co-led by existing...
December 22, 2021 07:00 ET | Source: Beta Bionics, Inc.

Beta Bionics Announces Data Lock of the Insulin-Only Bionic Pancreas Pivotal Trial and Enrollment into the Screening Protocol of the Bihormonal Bionic Pancreas Pivotal Trial

The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use.Not available for sale. The iLet® Bionic Pancreas is a pocket-sized, wearable...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right